Search
Minoxidil
go.drugbank.com/drugs/DB00350ApprovedInvestigationalA potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
Mixtures: MINOXIDIL 7% / NIACINAMIDE 4% s, FluMisch 5% MinoxidilCategories: Heterocyclic Compounds, 1-Ring, Arteriolar Smooth Muscle, Agents Acting OnOlopatadine
go.drugbank.com/drugs/DB00768ApprovedIt is a structural analog of [doxepin], which has a minimal anti-allergic activity. … [A1172] In comparison to other anti-allergenic ophthalmic medications, olopatadine displays a good comfort and tolerability profile since it does not cause perturbation of cell membranes.
Mixtures: OFNOL FRESH % 0.1 + %0.15 STERİL OFTALMİK ÇÖZELTİ, 1 ADETCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesDihydroergotamine
go.drugbank.com/drugs/DB00320ApprovedInvestigational[A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution … A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein inhibitorsSynonyms: (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide, 5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotamanCoccidioides immitis spherule
go.drugbank.com/drugs/DB11294ApprovedCoccidioides immitis spherule is a skin test antigen indicated to detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.
Asparaginase Erwinia chrysanthemi
go.drugbank.com/drugs/DB08886ApprovedInvestigationallymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase. … [L1448] L-asparaginase was first identified in 1963,[A236344] and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase
Synonyms: Erwinia L-asparaginase, L-asparaginase (Erwinia)Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[A245995] Ganaxolone, similar to its endogenous counterparts, is a positive allosteric modulator of GABA<sub>A</sub> receptors. … [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesSelumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigational[A193611] However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumours in Phase II trials … NF-1 is considered rare, with an estimated incidence of 1/3000 individuals.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesGallium nitrate
go.drugbank.com/drugs/DB05260ApprovedInvestigationalGallium nitrate is a nitrate salt of [DB14524], a heavy metal that has been used as a diagnostic agent.[A260816] Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone. … [A17097] GANITE, a product of gallium nitrate previously used to treat cancer-related hypercalcemia, was discontinued from marketing in the US for reasons other than safety or effectiveness.
Taurolidine
go.drugbank.com/drugs/DB12473ApprovedInvestigationalIt was first synthesized in the 1970s and was originally used as a prophylactic against intraperitoneal bacterial infections in patients with peritonitis. … [A263217] In November 2023, a catheter lock solution of taurolidine in combination with [heparin] - marketed as Defencath - received FDA approval under the Limited Population Pathway for Antibacterial
Categories: Heterocyclic Compounds, 1-RingProducts: Taurolin (Taurolidin "Geistlich") 2% - InstillationslösungRiociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for … Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate